Lieberman A, Kupersmith M, Estey E, Goldstein M
N Engl J Med. 1976 Dec 16;295(25):1400-4. doi: 10.1056/NEJM197612162952504.
Bromocriptine in high doses (up to 100 mg per day) was administered to 14 patients with advanced Parkinson's disease whose disorder was progressing despite optimum treatment with levodopa combined with a peripheral dopa decarboxylase inhibitor (carbidopa). In 10, bromocriptine (mean dose, 57 mg) induced a statistically significant (P less than 0.01) improvement in rigidity, tremor, bradykinesia, gait disturbance and total score. In seven patients levodopa with carbidopa was completely replaced by bromocriptine (mean dose, 70 mg), with improvement in four. Adverse effects were similar to those observed with levodopa and carbidopa, except that in individual patients abnormal involuntary movements and diurnal oscillations in performance (on-off effect) were decreased whereas orthostatic hypotension and mental changes were increased. Bromocriptine appears to be a major new agent in Parkinson's disease that is especially promising in patients no longer responding to levodopa.
对14例晚期帕金森病患者给予大剂量（每日高达100毫克）的溴隐亭治疗，这些患者尽管接受了左旋多巴与外周多巴脱羧酶抑制剂（卡比多巴）的最佳联合治疗，病情仍在进展。在10例患者中，溴隐亭（平均剂量57毫克）使强直、震颤、运动迟缓、步态障碍和总分有统计学意义的改善（P<0.01）。7例患者的左旋多巴与卡比多巴完全被溴隐亭（平均剂量70毫克）替代，其中4例病情改善。不良反应与左旋多巴和卡比多巴观察到的相似，只是个别患者的异常不自主运动和日间功能波动（开关效应）减少，而体位性低血压和精神改变增加。溴隐亭似乎是帕金森病中的一种重要新药，对不再对左旋多巴有反应的患者尤其有前景。
